EBITDA Summary of GenMont Biotech Incorporation

GenMont Biotech Incorporation's latest annual EBITDA in 2023 was 71.76 Million TWD , down -37.94% from previous year.
GenMont Biotech Incorporation's latest quarterly EBITDA in 2024 Q2 was 28.27 Million TWD , down -41.08% from previous quarter.
GenMont Biotech Incorporation reported an annual EBITDA of 115.64 Million TWD in 2022, down -29.75% from previous year.
GenMont Biotech Incorporation reported an annual EBITDA of 164.62 Million TWD in 2021, up 68.2% from previous year.
GenMont Biotech Incorporation reported a quarterly EBITDA of 28.27 Million TWD for 2024 Q2, down -41.08% from previous quarter.
GenMont Biotech Incorporation reported a quarterly EBITDA of 13.62 Million TWD for 2023 Q2, down -49.04% from previous quarter.

Annual EBITDA Chart of GenMont Biotech Incorporation (2023 - 2009)

Historical Annual EBITDA of GenMont Biotech Incorporation (2023 - 2009)

Year	EBITDA	EBITDA Growth
2023	71.76 Million TWD	-37.94%
2022	115.64 Million TWD	-29.75%
2021	164.62 Million TWD	68.2%
2020	98.58 Million TWD	1.21%
2019	98.06 Million TWD	-35.75%
2018	143.91 Million TWD	126.65%
2017	147.07 Million TWD	-5.03%
2016	69.92 Million TWD	471.89%
2015	49.81 Million TWD	104.58%
2014	-248.1 Million TWD	-443.85%
2013	77.56 Million TWD	9256.94%
2012	60.12 Million TWD	-70.42%
2011	74.6 Million TWD	-98.49%
2010	185.92 Million TWD	52.01%
2009	122.68 Million TWD	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	47.98 Million TWD	278.21%
2024 Q2	28.27 Million TWD	-41.08%
2023 Q2	13.62 Million TWD	-49.04%
2023 Q3	44.61 Million TWD	227.42%
2023 FY	- TWD	-37.94%
2023 Q4	20.56 Million TWD	-53.9%
2023 Q1	26.73 Million TWD	-17.16%
2022 Q4	32.27 Million TWD	57.02%
2022 FY	- TWD	-29.75%
2022 Q3	20.55 Million TWD	-25.19%
2022 Q2	27.47 Million TWD	-22.24%
2022 Q1	35.33 Million TWD	-42.29%
2021 Q1	44 Million TWD	179.25%
2021 FY	- TWD	68.2%
2021 Q4	61.23 Million TWD	73.63%
2021 Q3	35.26 Million TWD	46.19%
2021 Q2	24.12 Million TWD	-45.18%
2020 Q1	18.84 Million TWD	338.67%
2020 Q2	24.1 Million TWD	27.93%
2020 Q3	39.17 Million TWD	62.52%
2020 FY	- TWD	1.21%
2020 Q4	15.75 Million TWD	-59.77%
2019 FY	- TWD	-35.75%
2019 Q1	52.57 Million TWD	59.04%
2019 Q3	25.27 Million TWD	73.64%
2019 Q2	14.55 Million TWD	-72.32%
2019 Q4	4.29 Million TWD	-83.01%
2018 Q1	21.89 Million TWD	586.84%
2018 FY	- TWD	126.65%
2018 Q4	33.05 Million TWD	-31.52%
2018 Q3	48.27 Million TWD	73.62%
2018 Q2	27.8 Million TWD	26.98%
2017 Q2	19 Million TWD	2.73%
2017 FY	- TWD	-5.03%
2017 Q4	-4.49 Million TWD	-113.46%
2017 Q3	33.4 Million TWD	75.84%
2017 Q1	18.49 Million TWD	68.08%
2016 FY	- TWD	471.89%
2016 Q4	11 Million TWD	-20.06%
2016 Q3	13.76 Million TWD	-50.15%
2016 Q2	27.61 Million TWD	57.47%
2016 Q1	17.53 Million TWD	158.2%
2015 FY	- TWD	104.58%
2015 Q1	-656 Thousand TWD	99.76%
2015 Q2	3.21 Million TWD	590.09%
2015 Q3	39.8 Million TWD	1137.98%
2015 Q4	-30.13 Million TWD	-175.71%
2014 FY	- TWD	-443.85%
2014 Q3	-12.94 Million TWD	-220.37%
2014 Q1	13.85 Million TWD	517.16%
2014 Q4	-278.38 Million TWD	-2050.2%
2014 Q2	10.75 Million TWD	-22.38%
2013 Q4	-3.32 Million TWD	-113.95%
2013 FY	- TWD	9256.94%
2013 Q2	31.57 Million TWD	23.85%
2013 Q1	25.49 Million TWD	2267.32%
2013 Q3	23.81 Million TWD	-24.58%
2012 Q4	1.07 Million TWD	-98.11%
2012 Q2	5.53 Million TWD	247.84%
2012 Q1	-3.74 Million TWD	-126.56%
2012 Q3	57.05 Million TWD	931.34%
2012 FY	- TWD	-70.42%
2011 Q2	-15.79 Million TWD	-190.99%
2011 Q1	17.35 Million TWD	-55.3%
2011 FY	- TWD	-98.49%
2011 Q4	14.09 Million TWD	209.65%
2011 Q3	-12.85 Million TWD	18.62%
2010 Q2	51.04 Million TWD	-3.03%
2010 Q1	52.63 Million TWD	0.0%
2010 FY	- TWD	52.01%
2010 Q4	38.82 Million TWD	-10.64%
2010 Q3	43.44 Million TWD	-14.88%
2009 FY	- TWD	0.0%

Peer EBITDA Comparison of GenMont Biotech Incorporation

Name	EBITDA	EBITDA Difference
Apex Biotechnology Corp.	221.06 Million TWD	67.535%
Sinphar Pharmaceutical Co.,Ltd.	582.94 Million TWD	87.689%
Panion & Bf Biotech Inc.	327.21 Million TWD	78.067%
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	473.81 Million TWD	84.853%
Abnova (Taiwan) Corporation	81.2 Million TWD	11.626%
Adimmune Corporation	-512.42 Million TWD	114.005%
Tanvex BioPharma, Inc.	-1.75 Billion TWD	104.091%
Polaris Group	-1.38 Billion TWD	105.165%
Energenesis Biomedical CO.,LTD.	-244.57 Million TWD	129.344%
UnicoCell Biomed Co., Ltd.	-56.27 Million TWD	227.529%
PELL Bio-Med Technology Co. Ltd.	-353.17 Million TWD	120.321%

Global Stocks Search

GenMont Biotech Incorporation (3164.TW)

EBITDA Summary of GenMont Biotech Incorporation

Annual EBITDA Chart of GenMont Biotech Incorporation (2023 - 2009)

Historical Annual EBITDA of GenMont Biotech Incorporation (2023 - 2009)

Peer EBITDA Comparison of GenMont Biotech Incorporation